Clinical trial Recruiting at 1 site Observational Ages 18 and up

Immunosuppression and ICU-acquired MDROs in critically ill adults

Official title: Impact of Immunosuppression on Intensive Care Unit-acquired Multidrug-resistant Bacteria: a Prospective Multicenter Study in Europe

Run by University Hospital, Lille · NCT06652126 · Data updated 2026-11-12

This study tests how often ICU patients who are immunocompromised acquire or carry resistant bacteria, and how this relates to infections and outcomes.

More Critically Ill trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment1000 (estimated)
SponsorUniversity Hospital, Lille
Academic / other
Drugs / interventionsprednisone
Locations1 site (Lille)
StatusRecruiting
StartedMarch 19, 2025
Main results expectedDecember 1, 2029
Study endsDecember 1, 2029
Registry record updatedOctober 21, 2026
Trial IDNCT06652126 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years and older admitted to the ICU with anticipated stay > 48 hours, including both immunocompromised and immunocompetent patients.

Probably not a fit

Patients not at risk for ICU-acquired infections or those with very short ICU stays may be less likely to benefit from the study insights.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, multicenter study in ICUs focusing on ICU-acquired multidrug-resistant bacteria in adults, including both immunocompetent and immunocompromised patients. The project collects microbiological data to track colonization and infections by resistant pathogens after at least 48 hours in the ICU. It builds on prior findings that isolation measures may influence cross-transmission in immunocompromised patients. The aim is to characterize the frequency and patterns of ICU-MDR colonization and infection and explore factors associated with transmission. No interventional therapies are tested; the study analyzes real-world data to inform infection control priorities in ICUs.

Why it matters

Potential benefit: If successful, findings could improve infection control practices and reduce ICU stays and mortality related to resistant infections.

How similar studies have gone: Prior multicenter work suggests differential risk of MDR colonization and infection in immunocompromised patients, with some protective effects from isolation measures observed.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients aged 18 and over.
2. Admitted to intensive care and whose length of stay is greater than 48 hours (inclusion is at the 48th hour after admission).
3. Immunocompetent OR immunocompromised patients according to one of the following criteria:

   1. Solid cancer under treatment or in remission for less than 5 years (including cancers diagnosed during hospitalization in intensive care);
   2. Hematological malignancies under treatment or in remission for less than 5 years (including hematological malignancies diagnosed during hospitalization in intensive care);
   3. Neutropenia \< 0.7 G/L for ≥ 7 days;
   4. Solid organ transplants;
   5. Patients with systemic or transplant pathologies requiring treatment with corticosteroids (prednisone equivalent \> 10 mg/day) or other high-dose immunosuppressants for \> 28 days;
   6. Human Immunodeficiency Virus (HIV) infection with CD4+ \<200 μL;
   7. Genetic immune deficiency.
4. Patients undergoing invasive mechanical ventilation and/or vasopressive amines.
5. Persons who have given their non-opposition. For patients unable to give their non-opposition, this will be obtained from the trusted support person. The patient will be informed as soon as possible and asked to agree to participate in any further research.
6. Patients affiliated to a social security system.

Exclusion Criteria:

1. Minor patients (\< 18 years),
2. Length of stay in intensive care less than 48 hours,
3. Moribund patients.
4. Absence of BMR screening (rectal swab routinely, combined with nasal swab in some centers) within 48 hours of admission.
5. Refusal to participate in the study.
6. Vulnerable and/or susceptible patients according to one of the following criteria:

   1. Patients under legal protection (guardianship, curatorship, etc.);
   2. Patients in prison;
   3. Pregnant or breast-feeding women.
7. Patients without social security coverage.
8. Simultaneous participation in another interventional study that could interfere with the evaluation of primary and secondary endpoints (particularly in the case of participation in an interventional study that could modulate the risk of CAR or BMR-ARI).

Where it's running

  • chu de Lille
    Lille, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.